Scientists conducted ASCEND-4 research with 376 untreated patients who possessed NSCLC with ALK-positive status receiving ceritinib therapy or opposed to pemetrexed along with a platinum-based drug [18]. This evidence concerns the gene ALK and non-small cell lung carcinoma.